Clinical Trials Browser

Interventional × Pancreatic Neoplasms × LY3022855 × Clear all

NCT03153410 2025-01-09

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Phase EARLY_PHASE1 Completed

11 enrolled 14 charts

Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms